<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902002</url>
  </required_header>
  <id_info>
    <org_study_id>408-C-1804</org_study_id>
    <nct_id>NCT03902002</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic Study of Omaveloxolone in Subjects With Hepatic Impairment and Normal Hepatic Function</brief_title>
  <official_title>A Single Dose, Open Label Pharmacokinetic Study of Omaveloxolone in Subjects With Mild, Moderate, or Severe Hepatic Impairment, or With Normal Hepatic Function</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reata Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reata Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will examine the pharmacokinetics (PK) of omaveloxolone following a single oral&#xD;
      dose of omaveloxolone in subjects with mild, moderate, or severe hepatic impairment compared&#xD;
      to healthy subjects with normal hepatic function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 19, 2019</start_date>
  <completion_date type="Actual">January 27, 2020</completion_date>
  <primary_completion_date type="Actual">January 27, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum concentration (Cmax) of omaveloxolone in plasma</measure>
    <time_frame>15 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine maximum observed concentration (Cmax).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the the plasma omaveloxolone concentration-time curve (AUC)</measure>
    <time_frame>15 days</time_frame>
    <description>Pharmacokinetics will be assessed by blood sampling for omaveloxolone to determine area under the curve (AUC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Count of reported adverse events</measure>
    <time_frame>15 days</time_frame>
    <description>Safety and tolerability will be assessed by counting adverse events, as defined the Medical Dictionary for Regulatory Activities (MedDRA).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Hepatic Impairment</condition>
  <arm_group>
    <arm_group_label>Group 1: matched healthy subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2: subjects with mild hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3: subjects with moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 4: subjects with severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>On the morning of Day 1, following an overnight fast of at least 10 hours, a single oral dose of 150 mg omaveloxolone (3 × 50 mg capsules) will be administered with 240 mL of water. No food will be allowed for 4 hours post dose. Pharmacokinetic samples will be obtained from pre dose until 336 hours post dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omaveloxolone 50 mg capsules</intervention_name>
    <description>Capsules containing 50 mg of omaveloxolone</description>
    <arm_group_label>Group 1: matched healthy subjects</arm_group_label>
    <arm_group_label>Group 2: subjects with mild hepatic impairment</arm_group_label>
    <arm_group_label>Group 3: subjects with moderate hepatic impairment</arm_group_label>
    <arm_group_label>Group 4: subjects with severe hepatic impairment</arm_group_label>
    <other_name>RTA 408</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females, of any race, between 18 and 70 years of age, inclusive.&#xD;
&#xD;
          -  BMI between 18.0 and 38.0 kg/m2, inclusive, and body weight ≥ 50 kg.&#xD;
&#xD;
          -  Females will not be pregnant (or planning to get pregnant) or lactating at Screening&#xD;
             or Check in (Day 1), and females of childbearing potential and males will agree to use&#xD;
             contraception .&#xD;
&#xD;
          -  Male subjects must not donate sperm and female subjects must not donate ova from Check&#xD;
             in (Day 1) until 90 days after their dose of study drug.&#xD;
&#xD;
        Subjects with Normal Hepatic Function Only&#xD;
&#xD;
          -  Matched to subjects with mild, moderate, or severe hepatic impairment in sex, age (±&#xD;
             10 years), and BMI (± 20%).&#xD;
&#xD;
          -  In good health, determined by no clinically significant findings from medical history,&#xD;
             physical examination, 12 lead ECG, vital signs measurements, and clinical laboratory&#xD;
             evaluations (congenital non hemolytic hyperbilirubinemia [e.g., suspicion of Gilbert's&#xD;
             syndrome based on total and direct bilirubin] is not acceptable) at Screening and&#xD;
             Check in as assessed by the investigator (or designee).&#xD;
&#xD;
        Subjects with Hepatic Impairment Only&#xD;
&#xD;
          -  Documented chronic stable liver disease (Child Pugh Class A [mild], B [moderate], or C&#xD;
             [severe] at Screening); diagnosis of cirrhosis due to parenchymal liver disease. This&#xD;
             will exclude biliary liver cirrhosis or other causes of hepatic impairment not related&#xD;
             to parenchymal disorder:&#xD;
&#xD;
          -  'Documented' is defined by at least one of the following: medical history, physical&#xD;
             examination, hepatic ultrasound, computed axial tomography scan, magnetic resonance&#xD;
             imaging, and/or liver biopsy.&#xD;
&#xD;
          -  'Chronic stable' is defined as no clinically significant change in disease status&#xD;
             within the last 30 days, as documented by the subject's recent medical history (e.g.,&#xD;
             no worsening of clinical signs of hepatic impairment, or no worsening of total&#xD;
             bilirubin or prothrombin time [PT] by more than 50%).&#xD;
&#xD;
          -  Subjects with mild, moderate, or severe hepatic impairment may have medical findings&#xD;
             consistent with their hepatic dysfunction, as determined by medical history, physical&#xD;
             examination, 12 lead ECG, vital sign measurements, and clinical laboratory evaluations&#xD;
             at Screening and Check in (Day 1). Subjects with abnormal findings considered not&#xD;
             clinically significant by the investigator will be eligible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Significant history or clinical manifestation of any metabolic, allergic,&#xD;
             dermatological, renal, hematological, pulmonary, cardiovascular, gastrointestinal,&#xD;
             neurological, respiratory, endocrine, or psychiatric disorder, as determined by the&#xD;
             investigator (or designee).&#xD;
&#xD;
          -  History of significant hypersensitivity, intolerance, or allergy to any drug compound,&#xD;
             food, or other substance, unless approved by the investigator (or designee).&#xD;
&#xD;
          -  History of stomach or intestinal surgery or resection that would potentially alter&#xD;
             absorption and/or excretion of orally administered drugs (cholecystectomy will not be&#xD;
             allowed; uncomplicated appendectomy and hernia repair will be allowed).&#xD;
&#xD;
          -  Presence of any other condition (including surgery) known to interfere with the&#xD;
             absorption, distribution, metabolism, or excretion of medicines.&#xD;
&#xD;
          -  Ventricular dysfunction or history of risk factors for Torsade de Pointes (TdP; e.g.,&#xD;
             unexplained syncope, known long QT syndrome, heart failure, and cardiomyopathy).&#xD;
             Subjects will be excluded if there is a family history of long QT syndrome.&#xD;
&#xD;
          -  Evidence of hepatorenal syndrome and estimated glomerular filtration rate (eGFR) ≤ 60&#xD;
             mL/min/1.73 m2 or abnormal sodium and potassium levels, as determined by the&#xD;
             investigator (or designee), calculated using the Chronic Kidney Disease Epidemiology&#xD;
             Collaboration (CKD EPI) equation at Screening or Check in (Day 1).&#xD;
&#xD;
          -  Clinically significant physical examination abnormality, as determined by the&#xD;
             investigator (or designee).&#xD;
&#xD;
          -  Use or intend to use any medications/products known to alter drug absorption,&#xD;
             metabolism, or elimination processes, including St. John's wort, within 30 days prior&#xD;
             to dosing, unless deemed acceptable by the investigator (or designee).&#xD;
&#xD;
          -  Use of any sensitive substrates for cytochrome P450 (CYP)2C8, moderate or strong&#xD;
             inhibitors or inducers of CYP3A4/5, or substrates for p glycoprotein (P gp) within 30&#xD;
             days prior to study drug administration.&#xD;
&#xD;
          -  Consumption of grapefruit, grapefruit products, star fruit, star fruit products, or&#xD;
             Seville oranges within 72 hours prior to study drug administration (Day 1) and&#xD;
             throughout the study (until after the Follow up Visit).&#xD;
&#xD;
          -  History of alcoholism or drug/chemical abuse within 6 months prior to Check in (Day&#xD;
             1).&#xD;
&#xD;
          -  Alcohol consumption of &gt; 21 units per week for males and &gt; 14 units for females. One&#xD;
             unit of alcohol equals 12 oz (360 mL) beer, 1½ oz (45 mL) liquor, or 5 oz (150 mL)&#xD;
             wine within the 6 months prior to Check in (Day 1).&#xD;
&#xD;
          -  Positive urine drug screen or positive alcohol breath or urine test result at&#xD;
             Screening and Check in (Day 1), that is not otherwise explained by permitted&#xD;
             concomitant medications. A positive alcohol test may be repeated once at Screening. A&#xD;
             positive alcohol test may not be repeated at Check in (Day 1).&#xD;
&#xD;
          -  Positive human immunodeficiency virus test (Appendix 2).&#xD;
&#xD;
          -  Participation in a clinical study involving administration of an investigational drug&#xD;
             (new chemical entity) in the past 30 days or 10 half lives (if known), whichever is&#xD;
             longer, prior to dosing.&#xD;
&#xD;
          -  Current enrollment in another clinical study.&#xD;
&#xD;
          -  Receipt of blood products within 2 months prior to Check in.&#xD;
&#xD;
          -  Donation or loss of ≥ 550 mL blood from 3 months prior to Screening, plasma from 2&#xD;
             weeks prior to Screening, or platelets from 6 weeks prior to Screening.&#xD;
&#xD;
        Subjects with Normal Hepatic Function Only&#xD;
&#xD;
          -  Confirmed supine blood pressure &gt; 140 mmHg or &lt; 90 mmHg and/or supine diastolic blood&#xD;
             pressure &gt; 90 mmHg or &lt; 50 mmHg, or resting (supine) heart rate &lt; 45 beats per minute&#xD;
             (bpm) or &gt; 100 bpm at Screening or Check in (Day 1), with a QT interval corrected for&#xD;
             heart rate using Fridericia's method (QTcF) &gt; 450 ms for male subjects and &gt; 470 ms&#xD;
             for female subjects.&#xD;
&#xD;
          -  Positive hepatitis panel (Appendix 2).&#xD;
&#xD;
          -  Use of tobacco or nicotine containing products within 6 months prior to Check in (Day&#xD;
             1), or positive cotinine at Screening or Check in (Day 1).&#xD;
&#xD;
          -  Clinically significant abnormal laboratory values (clinical chemistry, hematology,&#xD;
             coagulation, and urinalysis), as determined by the investigator (or designee).&#xD;
&#xD;
          -  Significant history or clinical manifestation of hepatic disorder, as determined by&#xD;
             the investigator (or designee).&#xD;
&#xD;
          -  History or presence of liver disease or liver injury as indicated by any clinically&#xD;
             significant deviations from normal reference ranges in liver function tests, unless&#xD;
             approved by the investigator (or designee).&#xD;
&#xD;
          -  History of diabetes mellitus.&#xD;
&#xD;
          -  Use or intend to use any prescription medications/products other than prescribed&#xD;
             hormone replacement therapy, implantable, or intrauterine contraceptives within 30&#xD;
             days prior to dosing, unless deemed acceptable by the investigator (or designee).&#xD;
&#xD;
          -  Use or intend to use slow release medications/products considered to still be active&#xD;
             within 30 days prior to Check in (Day 1), unless deemed acceptable by the investigator&#xD;
             (or designee).&#xD;
&#xD;
          -  Use or intend to use any non prescription medications/products including vitamins,&#xD;
             minerals, and phytotherapeutic , herbal , or plant derived preparations within 7 days&#xD;
             prior to Check in (Day 1), unless deemed acceptable by the investigator (or designee).&#xD;
&#xD;
        Subjects with Hepatic Impairment Only&#xD;
&#xD;
          -  Confirmed supine blood pressure &gt; 150 mmHg or &lt; 90 mmHg and/or supine diastolic blood&#xD;
             pressure &gt; 90 mmHg or &lt; 50 mmHg, or resting (supine) heart rate &lt; 45 bpm or &gt; 100 bpm&#xD;
             at Screening or Check in (Day 1), with a QTcF &gt; 470 ms for both male and female&#xD;
             subjects.&#xD;
&#xD;
          -  History of clinically significant left sided heart disease and/or clinically&#xD;
             significant cardiac disease.&#xD;
&#xD;
          -  Values outside the normal range for liver function tests that are not consistent with&#xD;
             their hepatic condition, as determined by the investigator (or designee).&#xD;
&#xD;
          -  Use of a new medication, or a change in dose, for the treatment of hepatic&#xD;
             encephalopathy within 90 days prior to Check in (Day 1).&#xD;
&#xD;
          -  Use of prescription drugs within 30 days prior to Check in (Day 1), with the exception&#xD;
             of therapies for hepatic disease and treatment of associated disorders that had been&#xD;
             stable for at least 3 months prior to administration of study drug (Day 1) or&#xD;
             prescribed hormone replacement therapy, implantable, or intrauterine contraceptives.&#xD;
&#xD;
          -  Recent history of, or the treatment of, esophageal bleeding (within the past 180&#xD;
             days), unless banded.&#xD;
&#xD;
          -  History of unstable diabetes mellitus (as evidenced by hemoglobin A1c [HbA1c] ≥ 9.0%&#xD;
             at Screening). Concomitant medications for the treatment of diabetes mellitus must be&#xD;
             approved by the investigator (or designee), Sponsor, and Covance Medical Monitor.&#xD;
&#xD;
          -  Presence of a portosystemic shunt.&#xD;
&#xD;
          -  Recent history of paracentesis within 90 days prior to Check in (Day 1).&#xD;
&#xD;
          -  Current functioning organ transplant or awaiting an organ transplant.&#xD;
&#xD;
          -  Evidence of severe ascites.&#xD;
&#xD;
          -  Recent history of hepatic encephalopathy (Grade 2 or above) within 180 days prior to&#xD;
             Screening.&#xD;
&#xD;
          -  Smoke more than 10 cigarettes or use the equivalent tobacco or nicotine containing&#xD;
             products per day or inability to refrain from tobacco use 2 hours pre dose until 4&#xD;
             hours post dose.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Orange County Research Center</name>
      <address>
        <city>Tustin</city>
        <state>California</state>
        <zip>92780</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami, LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Clinical Research Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>March 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2019</study_first_posted>
  <last_update_submitted>March 16, 2020</last_update_submitted>
  <last_update_submitted_qc>March 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>RTA 408</keyword>
  <keyword>RTA 408 capsules</keyword>
  <keyword>Omaveloxolone</keyword>
  <keyword>Omaveloxolone capsules</keyword>
  <keyword>Hepatic impairment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

